← Back to Search

Monoclonal Antibodies

Imvotamab for Non-Hodgkin's Lymphoma

Phase 1 & 2
Waitlist Available
Research Sponsored by IGM Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least one bi-dimensionally measurable lesion (>1.5cm in it's longest dimension by computerized tomography (CT scan))
> 18 years of age: ECOG PS 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 5 years
Awards & highlights

Study Summary

This trial is testing a new drug, IGM-2323, for people with a certain type of cancer that has come back or is not responding to treatment. The trial will have two parts, first testing different doses of the drug to see what is safe, then expanding to a larger group of people to see if the drug is effective. The drug will be given intravenously.

Who is the study for?
Adults over 18 with certain types of Non-Hodgkin Lymphoma (NHL) who have tried at least two treatments, including anti-CD20 chemo-immunotherapy, and are not candidates for stem cell transplant. They must have a measurable lesion on a CT scan and be in good health otherwise.Check my eligibility
What is being tested?
The trial is testing imvotamab alone or combined with other therapies in patients with relapsed/refractory B-cell NHL. It includes dose-escalation to find safe amounts, combination therapy stages, and expansion cohorts specific to the type of lymphoma.See study design
What are the potential side effects?
Potential side effects of imvotamab may include reactions related to infusion such as fever or chills, organ inflammation, fatigue, blood disorders that can affect immune response and increase infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a tumor larger than 1.5cm detectable by CT scan.
Select...
I am over 18 and can care for myself with minimal assistance.
Select...
My lymphoma has returned or didn't respond to treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Frequency of Adverse Events
Overall Response Rate (ORR)
Secondary outcome measures
Duration of Response (DOR)
Objective Response Rate (ORR)

Trial Design

6Treatment groups
Experimental Treatment
Group I: Phase 2 (FL)Experimental Treatment1 Intervention
FL subjects will receive imvotamab via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data. No longer enrolling.
Group II: Phase 2 (DLBCL)Experimental Treatment1 Intervention
DLBCL subjects will receive imvotamab via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data. No longer enrolling.
Group III: Phase 1b (Combination)Experimental Treatment1 Intervention
Subjects will receive imvotamab via IV infusion weekly and loncastuximab tesirine via IV infusion every 3 weeks.
Group IV: Phase 1a (Q3W)Experimental Treatment1 Intervention
Subjects will receive imvotamab via intravenous (IV) infusion every 3 weeks. No longer enrolling.
Group V: Phase 1a (Prior bi-specific)Experimental Treatment1 Intervention
Subjects treated with prior bi-specifics will receive imvotamab via IV infusion weekly. No longer enrolling.
Group VI: Phase 1a (Dose Escalation)Experimental Treatment1 Intervention
Subjects will receive imvotamab via intravenous (IV) infusion weekly. No longer enrolling.

Find a Location

Who is running the clinical trial?

ADC Therapeutics S.A.Industry Sponsor
28 Previous Clinical Trials
2,200 Total Patients Enrolled
IGM Biosciences, Inc.Lead Sponsor
7 Previous Clinical Trials
272 Total Patients Enrolled
Wayne Godfrey, M.D.Study DirectorIGM Biosciences, Inc.

Media Library

IGM-2323 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04082936 — Phase 1 & 2
Non-Hodgkin's Lymphoma Research Study Groups: Phase 1a (Prior bi-specific), Phase 1a (Dose Escalation), Phase 1a (Q3W), Phase 2 (DLBCL), Phase 2 (FL), Phase 1b (Combination)
Non-Hodgkin's Lymphoma Clinical Trial 2023: IGM-2323 Highlights & Side Effects. Trial Name: NCT04082936 — Phase 1 & 2
IGM-2323 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04082936 — Phase 1 & 2
~5 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top